Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 75.30
OCLS's Cash to Debt is ranked higher than
64% of the 778 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.15 vs. OCLS: 75.30 )
Ranked among companies with meaningful Cash to Debt only.
OCLS' s Cash to Debt Range Over the Past 10 Years
Min: 0.31  Med: 8.41 Max: No Debt
Current: 75.3
Equity to Asset 0.69
OCLS's Equity to Asset is ranked higher than
60% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. OCLS: 0.69 )
Ranked among companies with meaningful Equity to Asset only.
OCLS' s Equity to Asset Range Over the Past 10 Years
Min: -0.21  Med: 0.5 Max: 0.8
Current: 0.69
-0.21
0.8
F-Score: 3
Z-Score: -17.19
M-Score: -3.45
WACC vs ROIC
6.19%
-376.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -68.43
OCLS's Operating margin (%) is ranked lower than
87% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.44 vs. OCLS: -68.43 )
Ranked among companies with meaningful Operating margin (%) only.
OCLS' s Operating margin (%) Range Over the Past 10 Years
Min: -584.75  Med: -72.12 Max: -21.84
Current: -68.43
-584.75
-21.84
Net-margin (%) -68.29
OCLS's Net-margin (%) is ranked lower than
87% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. OCLS: -68.29 )
Ranked among companies with meaningful Net-margin (%) only.
OCLS' s Net-margin (%) Range Over the Past 10 Years
Min: -530.35  Med: -74.43 Max: 27.33
Current: -68.29
-530.35
27.33
ROE (%) -106.25
OCLS's ROE (%) is ranked lower than
93% of the 753 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.76 vs. OCLS: -106.25 )
Ranked among companies with meaningful ROE (%) only.
OCLS' s ROE (%) Range Over the Past 10 Years
Min: -1759.66  Med: -179.16 Max: 46.27
Current: -106.25
-1759.66
46.27
ROA (%) -79.91
OCLS's ROA (%) is ranked lower than
94% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. OCLS: -79.91 )
Ranked among companies with meaningful ROA (%) only.
OCLS' s ROA (%) Range Over the Past 10 Years
Min: -121.52  Med: -82.32 Max: 22.39
Current: -79.91
-121.52
22.39
ROC (Joel Greenblatt) (%) -359.08
OCLS's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.07 vs. OCLS: -359.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OCLS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -926.75  Med: -634.42 Max: 541.28
Current: -359.08
-926.75
541.28
Revenue Growth (3Y)(%) -33.40
OCLS's Revenue Growth (3Y)(%) is ranked lower than
93% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. OCLS: -33.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OCLS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -33.4  Med: -6.5 Max: 53.5
Current: -33.4
-33.4
53.5
EBITDA Growth (3Y)(%) -9.60
OCLS's EBITDA Growth (3Y)(%) is ranked lower than
79% of the 564 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.30 vs. OCLS: -9.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OCLS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -29.3 Max: 370.5
Current: -9.6
0
370.5
EPS Growth (3Y)(%) -21.90
OCLS's EPS Growth (3Y)(%) is ranked lower than
83% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. OCLS: -21.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OCLS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -54  Med: -23.1 Max: 357.7
Current: -21.9
-54
357.7
» OCLS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with OCLS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:OTCPK:RLMD, NAS:ACUR, OTCPK:ALXA, OTCPK:CVSI, NAS:PARN, NAS:CBYL, NAS:APRI, OTCPK:AQSZF, AMEX:PVCT, AMEX:IGC, NAS:BNTC, NAS:EVOK, OTCPK:RSPID, OTCPK:AOLS, NAS:MYOS, OTCPK:MRPHF, OTCPK:GLDFF, OTCPK:KAYS, OTCPK:NUVPF, OTCPK:PTLFD » details
Traded in other countries:O8Z2.Germany,
Oculus Innovative Sciences Inc designs, produces and markets prescription and non-prescription products. It provides products for wound management, nursing home & home healthcare, dermatology and wound & skin care for consumers.

Oculus Innovative Sciences Inc was incorporated under the laws of the State of California in April 1999 as Micromed Laboratories, Inc. In August 2001, it changed its name to Oculus Innovative Sciences, Inc. In December 2006, it reincorporated under the laws of the State of Delaware. The Company develops, manufactures and markets a family of tissue care products that cure infections and, through a separate mechanism of action, enhance healing while reducing the need for antibiotics. Infection is a serious potential complication in both chronic and acute wounds, and controlling infection is a critical step in wound healing. The Company's platform technology, called Microcyn(r), is a proprietary solution of electrically charged oxychlorine small molecules designed to treat a wide range of organisms that cause disease (pathogens). These include viruses, fungi, spores and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus, or MRSA, and vancomycin-resistant Enterococcus, or VRE, in wounds, as well as Clostridium difficile (C. diff), a highly contagious bacteria spread by human contact. The Company's products compete with a variety of products used for wound cleaning, debriding and moistening, including sterile saline, and chlorhexadine-based products, and they also compete with a large number of prescription and over-the-counter products for the prevention and treatment of infections, including topical anti-infectives, such as Betadine, silver sulfadiazine, hydrogen peroxide, Dakin's solution and hypochlorous acid, and topical antibiotics, such as Neosporine, Mupirocin and Bacitracin. Government authorities in the United States at the federal, state and local levels and foreign countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, distribution, sampling, marketing, and import and export of pharmaceutical products, biologics and medical devices.

Ratios

vs
industry
vs
history
P/B 2.37
OCLS's P/B is ranked higher than
62% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. OCLS: 2.37 )
Ranked among companies with meaningful P/B only.
OCLS' s P/B Range Over the Past 10 Years
Min: 0.87  Med: 6.93 Max: 265.58
Current: 2.37
0.87
265.58
P/S 0.95
OCLS's P/S is ranked higher than
84% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. OCLS: 0.95 )
Ranked among companies with meaningful P/S only.
OCLS' s P/S Range Over the Past 10 Years
Min: 0.46  Med: 2.6 Max: 17.96
Current: 0.95
0.46
17.96
Current Ratio 2.97
OCLS's Current Ratio is ranked higher than
59% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. OCLS: 2.97 )
Ranked among companies with meaningful Current Ratio only.
OCLS' s Current Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.93 Max: 4.93
Current: 2.97
0.54
4.93
Quick Ratio 2.41
OCLS's Quick Ratio is ranked higher than
61% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. OCLS: 2.41 )
Ranked among companies with meaningful Quick Ratio only.
OCLS' s Quick Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.86 Max: 4.32
Current: 2.41
0.5
4.32
Days Inventory 76.87
OCLS's Days Inventory is ranked higher than
72% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.00 vs. OCLS: 76.87 )
Ranked among companies with meaningful Days Inventory only.
OCLS' s Days Inventory Range Over the Past 10 Years
Min: 35.89  Med: 67.39 Max: 76.87
Current: 76.87
35.89
76.87
Days Sales Outstanding 62.20
OCLS's Days Sales Outstanding is ranked higher than
63% of the 579 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.08 vs. OCLS: 62.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
OCLS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.97  Med: 62.07 Max: 109.59
Current: 62.2
39.97
109.59
Days Payable 62.74
OCLS's Days Payable is ranked lower than
55% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.81 vs. OCLS: 62.74 )
Ranked among companies with meaningful Days Payable only.
OCLS' s Days Payable Range Over the Past 10 Years
Min: 50.97  Med: 70.75 Max: 394.99
Current: 62.74
50.97
394.99

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -47.10
OCLS's 3-Year Average Share Buyback Ratio is ranked lower than
92% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. OCLS: -47.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OCLS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -64.5  Med: -29.6 Max: -1.2
Current: -47.1
-64.5
-1.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.03
OCLS's Price/Net Cash is ranked higher than
51% of the 201 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.90 vs. OCLS: 13.03 )
Ranked among companies with meaningful Price/Net Cash only.
OCLS' s Price/Net Cash Range Over the Past 10 Years
Min: 3.77  Med: 12.08 Max: 67.41
Current: 13.03
3.77
67.41
Price/Net Current Asset Value 2.61
OCLS's Price/Net Current Asset Value is ranked higher than
87% of the 441 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.54 vs. OCLS: 2.61 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OCLS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.9  Med: 10.08 Max: 263.42
Current: 2.61
1.9
263.42
Price/Tangible Book 2.32
OCLS's Price/Tangible Book is ranked higher than
69% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. OCLS: 2.32 )
Ranked among companies with meaningful Price/Tangible Book only.
OCLS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.05  Med: 6.81 Max: 184.67
Current: 2.32
1.05
184.67
Price/Median PS Value 0.38
OCLS's Price/Median PS Value is ranked higher than
94% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. OCLS: 0.38 )
Ranked among companies with meaningful Price/Median PS Value only.
OCLS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 1.21 Max: 6.41
Current: 0.38
0.21
6.41
Earnings Yield (Greenblatt) (%) -77.19
OCLS's Earnings Yield (Greenblatt) (%) is ranked lower than
97% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. OCLS: -77.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OCLS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -82.6  Med: 39.3 Max: 103.6
Current: -77.19
-82.6
103.6

More Statistics

Revenue (TTM) (Mil) $15.22
EPS (TTM) $ -2.96
Beta0.61
Short Percentage of Float3.03%
52-Week Range $3.57 - 7.15
Shares Outstanding (Mil)4.20

Analyst Estimate

Mar17 Mar18 Mar19
Revenue (Mil $) 16 19 23
EPS ($) -2.03 -1.23 -0.46
EPS w/o NRI ($) -2.03 -1.23 -0.46
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for OCLS

Headlines

Articles On GuruFocus.com
Experience a Unique Realm Of Science Fiction With Sony’s Virtual Reality Headset Mar 12 2015 
Focus on New Technologies Can Drive Facebook's Growth Jan 22 2015 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Feb 04 2011 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Nov 04 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 18,500 Shares Aug 09 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 18,500 Shares Aug 09 2010 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Aug 05 2010 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Feb 11 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 20,000 Shares Dec 09 2009 
Weekly CFO Buys Highlight: Information Services Group Inc., BioFuel Energy Corp., Oculus Innovative Nov 22 2009 

More From Other Websites
OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 8-K/A, Submission of Matters to a Vote of Security... Sep 19 2016
OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Sep 09 2016
Oculus Innovative Sciences Launches Lasercyn™ into U.S. Dermatology Market for Use Following Laser... Aug 30 2016
Oculus Innovative Sciences Launches Lasercyn™ into U.S. Dermatology Market for Use Following Laser... Aug 30 2016
Oculus Innovative Sciences Receives U.S. FDA Approval for New Post-Dermal-Procedures Product for... Aug 24 2016
Oculus Innovative Sciences Receives U.S. FDA Approval for New Post-Dermal-Procedures Product for... Aug 24 2016
OCULUS INNOVATIVE SCIENCES, INC. Financials Aug 18 2016
SECFilings.com: Oculus Innovative Sciences (OCLS) Tackling Eczema From the Inside Out and Outside In Aug 17 2016
Edited Transcript of OCLS earnings conference call or presentation 28-Jul-16 8:30pm GMT Aug 12 2016
Oculus Innovative Sciences Receives Australian Approvals to Market Sterile Microcyn®-Based... Aug 11 2016
Oculus Innovative Sciences Receives Australian Approvals to Market Sterile Microcyn®-Based... Aug 11 2016
OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 10-Q, Quarterly Report Aug 09 2016
SECFilings.com: OCLS Keeping in Step With Innovation and US Dermatology Market Penetration Aug 04 2016
OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Jul 29 2016
ETF’s with exposure to Oculus Innovative Sciences, Inc. : July 29, 2016 Jul 29 2016
Oculus Innovative Sciences Reports Financial Results for First Quarter of Fiscal Year 2017 Jul 28 2016
OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 28 2016
Oculus Innovative Sciences Reports Financial Results for First Quarter of Fiscal Year 2017 Jul 28 2016
Q1 2017 Oculus Innovative Sciences Inc Earnings Release - After Market Close Jul 28 2016
Oculus Innovative Sciences, Inc. :OCLS-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 Jul 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)